ACIP Meeting Report – Feb 4th 2022

Following the FDA approval of Moderna COVID-19 vaccine (Spikevax) for individuals 18 years and older on 31JAN2022, ACIP met today to review the complete package of data submitted with the BLA on this vaccine. At the end of the first portion of the meeting, the ACIP took a vote on the following policy question: Should vaccination with the Moderna COVID-19 vaccine (Spikevax, 2-dose primary series) be recommended for persons 18 years of age and older?, There was a unanimous vote in favor.

To view the CDC ACIP Meeting Report from February 4th 2022, see below.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

More SAFETY TEMPLATES

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023

Modified Vaccinia Ankara (MVA) vaccine platform: standardized template for collection of key information for risk/benefit assessment

October 4, 2023

Medigen COVID-19 protein vaccine: standardized template with key considerations for a benefit/risk assessment

April 6, 2023

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

August 19, 2022
View All

More Posts

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.